Repaglinide is a short-acting insulin secretagogue, which often results in considerable inter-individual variability in therapeutic efficacy when widely used in clinical setting. Repaglinide is used for diabetes mellitus type 2. Both repaglinide and metformin were effective in glycaemic control in new onset patients with type 2 diabetes in China. Repaglinide had no effect on insulin sensitivity, but it improved β-cell function.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
PPARD rs2016520 Polymorphism Affects Repaglinide Response in Chinese Han Patients with Type 2 Diabetes Mellitus.
Song JF, et al. Clin Exp Pharmacol Physiol. 2014 Oct 14. PMID: 25311380.
Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
Ma J, et al. J Diabetes Res. 2014;2014:294017. PMID: 25311380.
|Related Potassium Channel Products|
2,2,2-Trichloroethanol is an agonist for the nonclassical K2P channels TREK-1 (KCNK2) and TRAAK (KCNK4).
Nigericin is an antibiotic derived from Streptomyces hygroscopicus, it acts as an H+, K+, Pb2+ ionophore.
ML213 (CID-3111211) is a selective KV7.2 (KCNQ2) and KV7.4 (KCNQ4) channel opener, with EC50 values of 230 and 510 nM for KV7.2 and KV7.4, respectively.
CLP290 is a novel, orally available KCC2 modulator, highly selective for KCC2 over related Cl- transporters.
BMS-191011 is a potent BKCa channel opener (large-conductance Ca2+-activated potassium channel, KCa1.1).
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.